Fulfilling Sawai Group Vision 2030

Sawai Group Vision 2030

The World We Want to Build

A world where more people can receive healthcare services and live a full life with peace of mind among society.

Our Ideal State


A company with a strong presence that continues to contribute to people's health by providing a multifaceted mix of products and services that meet individual needs based on scientific evidence

▸ p. 15 **Medium-term Business Plan "Beyond 2027"**

▸ p. 33 **Progress on materiality**

The highest responsibility of our core generic drug business is ensuring we deliver a stable supply of our products. We aim to achieve a production capacity of 25 billion tablets by fiscal 2030. We are also accelerating investments in new business areas, including digital healthcare, medical devices, and disease prediction. Our goal is to evolve into a comprehensive healthcare group that supports people from the pre-disease and prevention stages through treatment, recovery, and ongoing health maintenance.

Our business evolution



We are now expanding beyond pharmaceutical treatment by accelerating the development of our digital and medical devices business. Through this business, we aim to deliver optimal care across every stage of the healthcare journey— from the pre-disease and prevention phase through recovery.

Performance results and targets

	FY2025 Actual	Vision 2030 for FY2030
Revenue*	¥201.7 billion	**¥310.0 billion**
Sales volume	17.1 billion tablets	**24.0 billion tablets**
Share of sales	15.8%	**25.0% or more**
Production capacity	20.5 billion tablets	**25.0 billion tablets or more**
ROE	5.9%	**13% or more**
ROIC	3.8%	**10% or more**

*Including new businesses

Japan's aging population and rising demand for medical treatment are expected to drive growth in the generic drugs market by approximately 700 million tablets annually through fiscal 2030. The Sawai Group plans to increase its market share by expanding its production capacity to support growth in sales volume that exceeds the expected market growth.